Adage Capital Partners
BBOT

Adage Capital Partners’s BridgeBio Oncology BBOT Stock Holding History

Adage Capital Partners’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.05M Hold
400,000
– – ﹤0.01% 846
2026
Q1 		$3.58M Sell
400,000
-1,000,000
-71% -$10.7M 0.01% 800
2025
Q4 		$17.5M Sell
1,400,000
-87,621
-6% -$1.06M 0.03% 538
2025
Q3 		$17.2M Buy
1,487,621
+87,621
+6% +$913K 0.03% 514
2025
Q2 		$14.9M Hold
1,400,000
– – 0.03% 518
2025
Q1 		$15.8M Hold
1,400,000
– – 0.03% 474
2024
Q4 		$14.7M Hold
1,400,000
– – 0.03% 511
2024
Q3 		$14.6M Hold
1,400,000
– – 0.03% 533
2024
Q2 		$14.3M Hold
1,400,000
– – 0.03% 523
2024
Q1 		$14.6M Buy
+1,400,000
New +$14.5M 0.03% 532

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Adage Capital Partners's BBOT Position: Q2 2026 in Review

Adage Capital Partners held its BridgeBio Oncology (BBOT) position steady in Q2 2026 at 400,000 shares worth $3.05M. The position accounts for ﹤0.01% of the portfolio, ranked #846.

Adage Capital Partners first reported a position in BBOT in Q1 2024 and has held it in 10 quarters since. The position peaked at $17.5M in Q4 2025. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Adage Capital Partners held 400,000 shares of BridgeBio Oncology worth $3.05M as of Q2 2026.
  • Adage Capital Partners left its BridgeBio Oncology share count unchanged in Q2 2026.
  • BridgeBio Oncology made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #846 holding.
  • Adage Capital Partners first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 10 quarters since.
  • Adage Capital Partners's BridgeBio Oncology position peaked at $17.5M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.